Showing results (1531-1540 of 1,904) with videos related to
Sort By:
Pageof 191
The Canadian Journal of Urology|June 11, 2019
Comparison of nocturia etiology in black and white male patientsMatthew R Epstein, Thomas F Monaghan, Johnathan A Khusid, et al.Clinical Cardiology|May 20, 2008
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromesEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.Clinical Cardiology|May 20, 2008
Investigating the mechanisms of hyporesponse to antiplatelet approachesEugene Braunwald, Dominick Angiolillo, Eric Bates, et al.The Journal of Clinical Psychiatry|May 4, 2007
Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled studyDavid Michelson, Lenard A Adler, Jay D Amsterdam, et al.American Journal of Preventive Medicine|January 7, 2023
Reporting of Important Social Determinants of Health in Pediatric Clinical TrialsChris A Rees, Amanda M Stewart, Elyse N Portillo, et al.Journal of Public Health Management and Practice : JPHMP|October 4, 2022
Implementation and Uptake of the Massachusetts Drug Supply Data Stream: A Statewide Public Health-Public Safety Partnership Drug Checking ProgramTraci C Green, Rebecca Olson, Cole Jarczyk, et al.Nature Materials|July 9, 2025
Encoding hierarchical 3D architecture through inverse design of programmable bondsJason S Kahn, Brian Minevich, Aaron Michelson, et al.Pain|December 28, 2010
Impact of responder definition on the enriched enrollment randomized withdrawal trial design for establishing proof of concept in neuropathic painDavid J Hewitt, Tony W Ho, Bradley Galer, et al.Journal of Thrombosis and Haemostasis : JTH|September 28, 2006
Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'A D Michelson, M D Linden, M I Furman, et al.Journal of Clinical Psychopharmacology|January 8, 2004
Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessmentJoachim F Wernicke, Lenard Adler, Thomas Spencer, et al.Pageof 191